IRIS
GARIPOLI, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.587
NA - Nord America 2.727
AS - Asia 1.418
SA - Sud America 411
Continente sconosciuto - Info sul continente non disponibili 73
AF - Africa 55
OC - Oceania 1
Totale 8.272
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.679
RU - Federazione Russa 1.685
SG - Singapore 589
CN - Cina 457
SE - Svezia 440
IT - Italia 380
IE - Irlanda 377
BR - Brasile 352
DE - Germania 144
HK - Hong Kong 136
GB - Regno Unito 116
UA - Ucraina 105
FR - Francia 101
PL - Polonia 86
VN - Vietnam 58
FI - Finlandia 57
IN - India 51
CA - Canada 23
BD - Bangladesh 22
BE - Belgio 21
ZA - Sudafrica 17
AR - Argentina 14
NL - Olanda 14
ES - Italia 13
ID - Indonesia 13
IQ - Iraq 12
MX - Messico 12
CO - Colombia 11
MA - Marocco 11
JP - Giappone 10
VE - Venezuela 10
EC - Ecuador 8
PK - Pakistan 8
TR - Turchia 7
PH - Filippine 6
IL - Israele 5
IR - Iran 5
JM - Giamaica 5
SI - Slovenia 5
AT - Austria 4
CZ - Repubblica Ceca 4
EG - Egitto 4
ET - Etiopia 4
KE - Kenya 4
MY - Malesia 4
PT - Portogallo 4
PY - Paraguay 4
SA - Arabia Saudita 4
TN - Tunisia 4
UY - Uruguay 4
UZ - Uzbekistan 4
AO - Angola 3
AZ - Azerbaigian 3
CL - Cile 3
GR - Grecia 3
JO - Giordania 3
NO - Norvegia 3
OM - Oman 3
PS - Palestinian Territory 3
RO - Romania 3
RS - Serbia 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BO - Bolivia 2
BY - Bielorussia 2
CR - Costa Rica 2
DZ - Algeria 2
EE - Estonia 2
EU - Europa 2
GE - Georgia 2
HU - Ungheria 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LV - Lettonia 2
NP - Nepal 2
PA - Panama 2
PE - Perù 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BW - Botswana 1
BZ - Belize 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CM - Camerun 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GD - Grenada 1
GT - Guatemala 1
HR - Croazia 1
KR - Corea 1
LT - Lituania 1
LY - Libia 1
MD - Moldavia 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
SR - Suriname 1
Totale 8.201
Salva come PNG Salva come JPEG
Città #
Moscow 458
Dublin 377
Ashburn 351
Chandler 344
Singapore 315
Dallas 278
Nyköping 218
Jacksonville 211
San Jose 165
Beijing 158
Hong Kong 136
Messina 85
Warsaw 81
Ann Arbor 72
Dearborn 69
The Dalles 66
Council Bluffs 63
Los Angeles 60
Princeton 55
Medford 53
New York 51
Cambridge 47
Lauterbourg 45
Des Moines 42
Boardman 31
Lancaster 30
Munich 30
Buffalo 27
Jinan 23
Ho Chi Minh City 22
Brussels 21
Rome 21
São Paulo 21
Tianjin 20
Woodbridge 20
Frankfurt am Main 19
Pune 18
Shenyang 16
Milan 15
Orem 15
Rio de Janeiro 15
Brooklyn 14
Hebei 13
Chicago 12
Guangzhou 12
Johannesburg 12
Wilmington 12
Redondo Beach 11
San Mateo 11
Haikou 10
Hangzhou 10
London 10
Nanchang 10
Zhengzhou 10
Catania 9
Chennai 9
Manchester 9
Phoenix 9
Santa Clara 9
Turku 9
Atlanta 8
Düsseldorf 8
Leawood 8
Montreal 8
Nanjing 8
Stockholm 8
Tokyo 8
Trento 8
Augusta 7
Changsha 7
Hanoi 7
Lanzhou 7
Ningbo 7
Shanghai 7
Taizhou 7
Belo Horizonte 6
Dong Ket 6
Jakarta 6
Porto Alegre 6
Ribeirão Preto 6
São Bernardo do Campo 6
Amsterdam 5
Brasília 5
Denver 5
Montes Claros 5
Murska Sobota 5
Paris 5
Redwood City 5
Shenzhen 5
Addis Ababa 4
Bogotá 4
Bragança Paulista 4
Casablanca 4
Columbus 4
Contagem 4
Edinburgh 4
Goiânia 4
Guarulhos 4
Helsinki 4
Hyderabad 4
Totale 4.598
Salva come PNG Salva come JPEG
Nome #
RESEZIONE DI METASTASI EPATICHE DA CANCRO DEL COLON DOPO "SHRINKAGE" DI MALATTIA OTTENUTO CON FOLFIRI + CETUXIMAB 280
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 241
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations 236
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 227
Endoscopic mucosal resection of a large inflammatory fibroid polyp (Vanek's tumor): a case report 210
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 206
Incidence and Outcomes of Bone Metastases. Evaluation of BTAs Therapy, Pain Relief and Quality of Life: Experience from a Single Cancer Center 205
"Young-old",Old-old", Oldest-old" and breast cancer: Cancer surrender prohibited. Our challenge for 87 patients 201
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 198
A randomized factorial trial of sequential doxrubicina and CMF vs CMF and chemoterapy alone vs chemoterapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer 188
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 188
Esperienze cliniche in oncologia:Donna affetta da crcinoma del pancreas con componente neuroendocrina funzionante 187
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 186
Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen 185
Thyroid gland metastasis from breast cancer as sixth site of disease:A Case Report 185
Endocrine toxicity of immune checkpoint inhibitors (anti-PD-1/PD-L1) in advanced cancer 183
Amifostine in conjuction with G-CSF enhances chemoterapy mobilization of peripheral blood progenitor cell 178
Men with Breast Cancer: 15 Cases 177
gemcitabine and pegylated liposomial doxorubicin in recurrent epithelial ovarian cancer (REOC).Preliminary report a phase II study 175
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications. 173
Breast. La terapia primaria: stato dell'arte 172
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 167
Il ruolo dell'ormonoterapia nel carcinoma della mammella in eta' geriatrica 165
Second line chemoterapy in patients with metastatic colorectal cancer(MCRC):our experience 165
Sustainability of Eribulin treatment for patients with metastatic breast cancer: is the cost of the drug related to the benefit produced (Effectiveness and Safety)? A single center experience 161
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 160
Combination of Gemcitabine (GEM and Liposomal Pegylate Doxorubicin (PLD) in recurrent/ metastatic breast carcinoma: a phase II study. 159
CIRCULATING PLASMA CELLS IN MULTIPLE MYELOMA: CORRELATION WITH DISEASE STAGE 157
Relapsed or refractory extranodal DLBCL treated with lenalidomide: A single center study 157
Impact of integrated treatments on patient management in solid tumors: From diagnosis to palliative care. 152
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 150
Gemcitabine (GEM) and liposomal doxorubicin (PLD) in recurrent/metastatic breast carcinoma: A phase II study 143
Circulating plasma cells in Multiple Myeloma correlation with disease stage 140
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 138
Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. 128
ZD 1839 IRESSA IN HEAVELY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) ASSESSMENT OF TOLERABILITY AND THE CLINICAL BENEFIT 125
Resistance to PGE(2) inhibition of PWM-stimulated lymphocytes from neoplastic patients 120
L'eritropoietina nel trattamento dell'anemia associata alle sindromi mielodisplastiche 120
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications 106
The interplay between burnout risk and attachment styles among palliative care practitioners 106
Safety and clinical activity of trastuzumab (TSM) containing therapies in heavily pretreated patients with metastatic breast cancer (MBC): A five-year experience 101
Risk of burnout in a sample of oncology healthcare professionals working in a hospital oncology unit with hospice and relationship with dysfunctional metacognitive beliefs 101
Safety of trastuzumab-containing therapies in elderly women with metastatic breast cancer. 100
Terapia con r-IL2 a basse dosi in due pazienti con leucemia mieloide cronica(LMC) in fase blastica 98
Temozolamide plus oral vinorelbine in the treatment of brain metastases from solid tumours in heavily pre- treated patients. 93
Polycythemia vera and essential thrombocytemia treated with IFN-ALPHA2a: Evidence of a significant clinical activity and molecular response. 93
Impiego della fish nello studio della fusione BCR-ABL in pazienti con leucemia mieloide cronica 92
Ruolo della capecitabinanei tumori gastroentericiDalla monoterapia all'associazione nel trattamento della malattia metastatica del colon-retto:ruolo della capecitabina 92
SAFETY OF PEGILATED LIPOSOMAL DOXORUBICIN AND GEMCITABINE IN ELDERLY WOMEN (>65 YEARS)WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER 90
Southern Bloting:Tecniche ed applicazioni 90
Safety and activity of trastuzumab (TRA) containing therapies as treatment of metastatic breast cancer(MBC): a five year experience. 88
Preliminary results of a phase II study of amifostine for patients with myelodisplastic syndrome 85
Terapia con r-IL-2 a basse dosi in pazienti con mieloma multiplo(MM) sottoposti a terapia con Melphalan a dosi intermedie e reinfusione di cellule staminali periferiche 83
Mobilization of breast cancer cells after priming with cyclophosphamide and G-CSF 81
null 52
null 33
Totale 8.272
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.575
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.575
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022379 0 0 20 15 13 5 24 15 5 101 56 125
2022/20231.241 92 124 56 129 85 117 23 83 470 4 44 14
2023/2024293 20 47 15 27 21 89 10 11 2 13 7 31
2024/20251.139 7 14 14 82 60 46 34 219 312 96 90 165
2025/20263.568 174 187 274 179 296 791 462 479 489 120 63 54
2026/2027174 52 111 11 0 0 0 0 0 0 0 0 0
Totale 8.272